BIOSPECIMEN CORE - CORE D: ABSTRACT Biomarkers for Older Controls At Risk for Dementia (BIOCARD) STUDY The Biospecimen Core (Core D) is responsible for all aspects of cerebrospinal fluid (CSF) and blood collection, storage, and analysis.
The aims of the Biospecimen Core are:
The specific aims of Biospecimen Core are: (1) Collect, catalog, and store CSF and blood specimens from participants in the BIOCARD study and from patients in the Johns Hopkins CSF Disorders Center (the latter to be used for exploratory analyses). CSF collection will be reinitiated biannually in the BIOCARD cohort, to add to the existing specimens. (2) Perform AlzBio3 assays for CSF A?1-42, total tau, and ptau-181 and an MSD assay for A?1-42 on all newly collected CSF specimens from BIOCARD participants and from well characterized patients in the Johns Hopkins CSF Disorders Center, and compare the validity of the two assays for A?1-42. (3) Examine the utility of new CSF assays as Alzheimer's disease (AD) biomarkers, using samples from patients in the Johns Hopkins CSF Disorders Center for discovery, and from participants in the BIOCARD cohort for validation. These assays will include: (a) a multiplexed assay for inflammatory markers, (b) a proteomics assay for synaptic markers and (c) a metabolomic assay for small molecules.
|Sacktor, Ned; Soldan, Anja; Grega, Maura et al. (2017) The BIOCARD Index: A Summary Measure to Predict Onset of Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 31:114-119|
|Pettigrew, Corinne; Soldan, Anja; Sloane, Kelly et al. (2017) Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. Neuroimage Clin 16:439-446|
|Tward, Daniel; Miller, Michael; Trouve, Alain et al. (2017) Parametric Surface Diffeomorphometry for Low Dimensional Embeddings of Dense Segmentations and Imagery. IEEE Trans Pattern Anal Mach Intell 39:1195-1208|
|Gross, Alden L; Hassenstab, Jason J; Johnson, Sterling C et al. (2017) A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. Alzheimers Dement (Amst) 8:147-155|
|Cai, Qing; Wang, Mei-Cheng; Chan, Kwun Chuen Gary (2017) Joint modeling of longitudinal, recurrent events and failure time data for survivor's population. Biometrics 73:1150-1160|
|Varma, V R; Varma, S; An, Y et al. (2017) Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. Mol Psychiatry 22:13-23|
|Pettigrew, Corinne; Soldan, Anja; Zhu, Yuxin et al. (2017) Cognitive reserve and cortical thickness in preclinical Alzheimer's disease. Brain Imaging Behav 11:357-367|
|Mori, Susumu; Kageyama, Yusuke; Hou, Zhipeng et al. (2017) Elucidation of White Matter Tracts of the Human Amygdala by Detailed Comparison between High-Resolution Postmortem Magnetic Resonance Imaging and Histology. Front Neuroanat 11:16|
|Soldan, Anja; Pettigrew, Corinne; Cai, Qing et al. (2017) Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease. Neurobiol Aging 60:164-172|
|Leoutsakos, J-M; Gross, A L; Jones, R N et al. (2016) 'Alzheimer's Progression Score': Development of a Biomarker Summary Outcome for AD Prevention Trials. J Prev Alzheimers Dis 3:229-235|
Showing the most recent 10 out of 42 publications